Galectin-1, The New Player in Staging and Prognosis of COVID-19

Sofija Sekulic

University of Kragujevac, Faculty of Medical Sciences, Department of Infectious disease

Nevena Gajovic

University of Kragujevac, Faculty of Medical Sciences, Center for Molecular Medicine and Stem Cell Research,

Milena Jurisevic

University of Kragujevac, Faculty of Medical Sciences, Department of Clinical pharmacy

Marina Jovanovic (✉ marinna034@gmail.com)

University of Kragujevac, Faculty of Medical Sciences, Department of Internal medicine

Biljana Popovska Jovicic

University of Kragujevac, Faculty of Medical Sciences, Department of Infectious disease

Nebojsa Arsenijevic

University of Kragujevac, Faculty of Medical Sciences, Center for Molecular Medicine and Stem Cell Research,

Zeljko Mijailovic

University of Kragujevac, Faculty of Medical Sciences, Department of Infectious disease

Marina Jovanovic

University of Kragujevac, Faculty of Medical Sciences, Department of Otorinolaringology

Zana Dolicanin

State University of Novi Pazar, Department of Biomedical sciences

Ivan Jovanovic

University of Kragujevac, Faculty of Medical Sciences, Center for Molecular Medicine and Stem Cell Research,

Research Article

Keywords: galectin-1, COVID-19, prognostic marker

Posted Date: September 3rd, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-830345/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Galectin-1, the new player in staging and prognosis of COVID-19

Running title: Galectin-1 in COVID-19 progression

Sofija Sekulic¹, Nevena Gajovic², Milena Jurisevic³, Marina Jovanovic*⁴, Biljana Popovska Jovicic¹, Nebojsa Arsenijevic^{2, 5}, Zeljko Mijailovic¹, Marina Jovanovic⁶, Zana Dolicanin⁷, Ivan Jovanovic²

¹ University of Kragujevac, Faculty of Medical Sciences, Department of Infectious disease, Kragujevac, 34000, Serbia

² University of Kragujevac, Faculty of Medical Sciences, Center for Molecular Medicine and Stem Cell Research, Kragujevac, 34000, Serbia

³ University of Kragujevac, Faculty of Medical Sciences, Department of Clinical pharmacy, Kragujevac, 34000, Serbia

⁴ University of Kragujevac, Faculty of Medical Sciences, Department of Internal medicine, Kragujevac, 34000, Serbia

⁵ Public health institute Kragujevac, Kragujevac, 34000, Serbia

⁶ University of Kragujevac, Faculty of Medical Sciences, Department of Otorinolaringology, Kragujevac, 34000, Serbia

⁷ State University of Novi Pazar, Department of Biomedical sciences, Novi Pazar, 36300, Serbia

Correspondence:

Marina Jovanovic*, MD PhD

University of Kragujevac, Faculty of Medical Sciences, Department of Internal medicine, Kragujevac, 34000, Serbia

Svetozara Markovica 69, 34000 Kragujevac, Serbia

Tel +38134306800, Fax. +38134306800112

E-mail: marinna034@gmail.com

Key words: galectin-1, COVID-19, prognostic marker

Abstract

Background A new virus from the group of coronaviruses was identified as the cause of atypical pneumonia and called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and disease called Corona Virus Disease (COVID-19). During the cytokine storm, the main cause of the death, proinflammatory cytokines are released which stimulate further tissue destruction. Galectin-1 is pleiotropic cytokine involved in many immune and inflammatory processes and its role in COVID-19 is still unknown. **Objective** The aim of this study was to determine systemic values of galectin-1 and correlations between gal-1 and proinflammatory cytokines and clinical parameters during COVID-19 progression. **Design** Observational and cross-sectional study. **Patients** 210 COVID-19 patients were included and divided into mild, severe or critical group according to COVID-19 severity. **Main Measures** Serum levels of IL-1 β , IL-6, IL-10, IL-23, IL-33 and galectin-1 were measured using sensitive enzyme-linked immunosorbent assay (ELISA) kits. **Key Results** Systemic levels of IL-1 β , IL-6, IL-10, IL-23, IL-33 and galectin-1 were significantly higher in stage III of COVID-19 patients compared to stage I and II. There were no significant differences in ratio between Galectin-1 and IL-10 with proinflammatory cytokines. Positive correlation was detected between Gal-1 and IL-1 β , IL6, IL-10, IL-23 and IL-33. Gal-1 positively correlated with chest radiographic finding, dry cough and headache and negatively correlated with normal breathing sound. **Conclusions** Linear regression model and ROC curve analysis point on Gal-1 as significant predictors for COVID-19 severity. Presented results implicate on Gal-1 and IL-10 dependent immunomodulation. The precise mechanism of Gal-1 effect in COVID-19 and its potential as a stage marker of disease severity is still to be clarified.

INTRODUCTION

COVID-19 is an infectious respiratory disease caused by the novel coronavirus, named as severe acute respiratory syndrome–corona virus 2 (SARS-CoV2). (1). Briefly after COVID-19 outbreak in China, the disease spread around the world and the World Health Organization declared a pandemic¹. The clinical presentation of COVID-19 can vary from asymptomatic to acute respiratory distress syndrome (ARDS) and respiratory insufficiency^{2, 3}. Most common underlying mechanism of respiratory failure in patients with COVID-19 is characterized by rapid activation of proinflammatory cytokines and inflammatory cell recruitment in the lungs (e. g. cytokine storm)^{4, 5}. An increased concentration of IL-6, TNF- α , IL-2, IL-8, IL-1 β , G-CSF, IL-17, GM-CSF, IL10, MCP1, MIP1 α , chemokines, galectins in serum, was detected in COVID-19 patients⁶⁻⁸. Interestingly, role of immunosuppressive cytokines, especially IL-10 may also contribute to COVID-19 induced damage of the lungs in latter stages of the disease⁹.

Galectins are oligosaccharides chain complexes located on the cell surface and play an important role in regulating immune reactions and inflammatory responses^{10, 11, 12}. Galectin-1 (Gal-1) was the first identified protein in this family. Even though it is known that Gal-1 has many regulatory functions in viral infections, to date, the role of Gal-1 in immunopathogenesis of the COVID-19 disease has not been clarified. Until now, only one study by Kazancioglu et al investigated potential role of galectins in SARS-CoV-2 induced inflammation. The results imply that levels of galectins (Gal-1 and Gal-3) are elevated in COVID-19 patients in comparison to healthy patients¹³. The aim of this study was to determine the association of Gal-1 and innate immunity cytokines such as IL-1 β , IL-6, IL-10, IL-23, IL-33 with disease severity, alongside with clinical and biochemical features as well as CXR lung findings on disease severity in 210 patients with COVID-19.

Results

Clinical features of COVID-19 patients

All of 210 patients included in the study met the criteria for COVID-19¹⁴ and were classified into the three groups according to disease severity. The median age of mild group (54. 9 $\pm$ 1. 7) was significantly different from that of severe patients (59. 5 $\pm$ 1. 3) or critical (61. 3 $\pm$ 1. 4) (Table 1). Among all of them, 135 (57, 14%) were male. The analysis revealed a higher percentage of male

patients and a lower percentage of female patients in group II and III with statistical significance ($p = 0.041$; Table 1). The most frequent auscultatory finding in group I was attenuated breathing sound in 44.3% of patients, with CXR findings described like interstitial thickening in 51.4%, focal consolidation in 28.5% and normal findings in 20%. In group II, 58.5% of patients had auscultatory attenuated breathing sound, 48.5% audible crackles diffusely with CXR findings described like multifocal consolidation in 44.2% of hospitalized patients, focal consolidation in 30% and interstitial thickening in 25.7%. In group III, auscultatory 90% of patients had audible crackles diffusely, attenuated breathing sound in 85.7% with diffuse alveolar changes / ARDS on CXR findings. Only 10 (14.2%) among this group had multifocal consolidation. Compared with mild group, the severe and critical group were more likely to have dyspnea, fatigue, auscultatory audible crackles diffusely. The percentage of patients with these findings was significantly higher than in the mild group ($p < 0.05$; Table 1), which is in line with CXR findings of the patients. None of the patients in the severe and critical group had normal CRX finding, interstitial thickening or focal consolidation zones (CRX I, II, III), and none of the patients in the mild group had multifocal consolidation zones or diffuse alveolar changes / ARDS (CRX IV, V) ($p=0.000$) (Table 1).

In patients with severe and critical features, an increase in neutrophil count ($p=0.001$), urea ($p=0.018$), AST ($p=0.001$), ALT ($p=0.001$), BILD ($p = 0.018$), CK ($p=0.012$), LDH ($p=0.001$), D-dimer ($p=0.001$), CRP ($p=0.001$), PCT ($p=0.001$), Ferritin ($p=0.001$) was noted, with reduced lymphocyte count ($p=0.001$), monocyte count ($p=0.006$), decreased levels of albumin ($p=0.001$) and lower values of SaO_2 ($p=0.001$) and pO_2 ($p=0.001$) (Table 2). There were no statistically significant differences in white blood cell count, erythrocytes and platelets, hemoglobin; levels of plasma glucose, creatinine, BILT, K^+ , Na^+ , Fe, pH of blood, pCO_2 (Table 2).

Patients with the more severe form of COVID-19 had increased systemic values of Gal-1

Serum pro- and anti-inflammatory cytokines of interest were measured in COVID-19 patients. Systemic values of IL- 1β ($p=0.001$), IL-6 ($p=0.001$), IL-10 ($p=0.026$), IL-23 ($p=0.001$), IL-33 ($p=0.001$), and Gal-1 ($p=0.001$) were significantly higher in stage III of COVID-19 patients compared to patients in stage I and II (Figure 1).

Unchanged flow of ratios of Gal-1 and IL-10 with proinflammatory cytokines during COVID-19 development

Analyses of the ratios of Gal-1 and IL-10 with IL-1 β , IL-6, IL-23 and IL-33 were done. There were no statistically significant differences in the ratios of Gal-1/IL-1 β , Gal-1/IL-6, Gal-1/IL-23, Gal-1/IL-33 and Gal-1/IL-10 as well as IL-10/IL-1 β , IL-10/IL-6, IL-10/IL-23, IL-10/IL-33 between defined groups of COVID-19 patients (Figure 2).

The strongest correlation between Gal-1 and pro- and anti-inflammatory cytokines in stage III of COVID-19

Analyses of correlation between Gal-1 and pro- and anti-inflammatory cytokines within stages of COVID-19 were made. In stage I of COVID-19, strong positive correlation was detected between Gal-1 and IL-33 ($p=0.00$). Analyses of patients in stage II of COVID-19 revealed a moderate positive correlation between Gal-1 and IL-1 β ($p=0.004$) and strong positive correlations between Gal-1 and IL-23 ($p=0.001$) and IL-33 ($p=0.001$) (Table 3). In stage III of COVID-19 patients, moderate positive correlation was noticed between Gal-1 and IL-1 β ($p=0.001$) and IL6 ($p=0.005$) and strong positive correlation between Gal-1 and IL-10 ($p=0.001$), IL-23 ($p=0.001$) and IL-33 ($p=0.001$) (Table 3).

Gal-1 correlates with clinical parameters of COVID-19

Analyses of correlation between Gal-1 and clinical parameters of COVID-19 were made. The results showed weak positive correlation between Gal-1 and dry cough ($r=0.242$; $p=0.001$) and headache ($r=0.158$; $p=0.034$), while weak negative correlation was detected between Gal-1 and normal breathing sound ($r=0.151$; $p=0.043$). Moderate positive correlation was detected between Gal-1 and chest radiographic findings ($r=0.352$; $p=0.001$).

Regression model for independent variables, including demographic features of the patients, clinical, biochemical parameters, serum levels of proinflammatory, anti-inflammatory cytokines and dependent variable (COVID-19 severity) showed significant results (Table 4). Advanced age and male sex are predictors for development of more severe form of COVID-19. Clinical manifestations such as dyspnea, fatigue and crackles are in positive linear association with COVID-19 severity. Analyses of laboratory findings also showed significant linear association with COVID-19 severity. Lymphocyte and monocyte count and albumin level were in negative

linear association with COVID-19 severity. Parameters pO₂ and SaO₂ were also in significant negative association with COVID-19 severity. Analyses of cytokines have shown that serum levels of IL-1 β , IL-6, IL-10, IL-23, IL-33 and Gal-1 are in significant positive association with increased COVID-19 severity (Table 4).

Examination of ROC curve demonstrates that Gal-1 can be a potential marker for stage II (sensitivity 89.5%, specificity 23.4%; cut off: 3959 pg/ml) and stage III detection (sensitivity 72.2%, specificity 25.9%; cut off: 9359 pg/ml) in COVID-19 patients.

Discussion

In this study, we comprehensively analyzed the relationship between Gal-1 and innate immunity cytokine profile, clinical, biochemical outcomes, and radiographic findings with disease severity. This was a cross-sectional study with only one time point evaluation, which is a limitation of our research. All of 210 COVID 19⁺ patients classified into the mild, severe and critical group.

Critically ill patients were mostly male and older compared to patients with mild to severe form of the disease, which indicate that gender and age correlated with disease severity. This was consistent with study by Hu et al.¹⁵ in which researchers suggested that age and gender may be indicators for poor outcome. In our study percentage of patients with dyspnea, fatigue, auscultatory audible crackles diffusely was significantly higher in severe and critical groups than in the mild one (Table 1).

Increased levels of neutrophil count, urea, AST, ALT, BIL, CK, LDH, D-dimer, CRP, PCT, Ferritin, reduced lymphocyte and monocyte count, decreased levels of albumin, and lower values of SaO₂ and pO₂ are associated with the severity of COVID-19. These findings are also confirmed by linear regression analysis (Table 4). Our findings are in accordance with recent studies¹⁶⁻¹⁸. Significantly higher sera levels of PCT were observed in severe and critical group in comparison to the mild group. As PCT levels are increased in sepsis, systemic inflammatory response syndrome bacterial, fungal, and parasitic infections, but not in viral infections, higher levels of this marker can suggest the possibility of multiple infections or cytokine storm in critically ill patients^{19, 20}. Increased levels of AST, ALT, DBIL, CK, LDH, D-dimer, suggested that SARS-CoV-2 infection may be associated with thrombosis, myocardia injury, hepatic injury and other related organ damage²¹. Although higher values of white blood cell count, thrombocyte

count, glucose, creatinine, Fe, BILT and lower values of hemoglobin, K⁺ and Na⁺ were detected in patients with severe and critical stage of COVID-19, statistical significance was not reached (Table 2). There was significant difference between CXR findings in mild, severe and critical group. In mild group the most common radiographic finding described as interstitial thickening (CXR II), in severe as multifocal consolidation zones (CXR IV) and in critical group as diffuse alveolar damage / ARDS (CXR V). Less common CXR lung findings in mild group were described like normal or focal consolidation zones (CXR I, III), in severe (CXR II, III), while in critical group none of the patients had CRX I, II, III.

We analyzed systemic levels of IL-1 β , IL-6, IL-10, IL-23, IL-33 and galectin-1. Galectin-1, member of carbohydrate-binding protein family, is expressed in normal and in pathological cells and possesses variable biological functions²². The role of Galectin-1 in progression of some type of virus infections is known. Bao et al. showed that in *in vivo* model, treatment with Galectin-1 decreased viral titer and inflammatory cell infiltrations in lungs of mice infected with H1N1pdm09 virus, stimulates production of proinflammatory cytokines and chemokines in serum and bronchoalveolar lavage fluid²³. During Influenza virus infection, level of Gal-1 was increased in lungs of infected mice, while Gal-1 knock-out mice were more prone to Influenza virus infection compared to wild-type group. Results with exogenous application of Gal-1 suggesting that Gal-1 acts in antiviral way by tied up to viral surface and reduced its infectivity²⁴. Also, it is confirmed that Gal-1 acts as adhesive molecule that enables attachment of HIV-1 virus to target cells thereby stimulating virus attachment and promoting infection²⁵. There are no data regarding the effect of Galectin-1 on infectivity of SARS-CoV-2 virus. Our results showed that patients in the critical stage of disease, III had the highest level of Gal-1 compared to patients in stage I and II (Figure 1). These results are in line with previous studies suggesting that level of Galectin-1 increases during disease progression and stimulate virus progression.

It is known that Gal-1 can have opposite role in immune responses²². As immunostimulative molecule, previous study have shown that Gal-1 induced pro-inflammatory function of TNF- α thus facilitating inflammation in Sertoli cells²⁶. On contrary, Motran et al. showed that Gal-1 stimulates apoptosis of Th1 cells and production of pro-Th2 cytokines²⁷. Anti-inflammatory role of Gal-1 is reflected in the fact that it converted macrophages from their proinflammatory to anti-inflammatory profile thus terminating the inflammation²⁸. Our previous work revealed

predominance of Gal-1 over proinflammatory cytokines in patients with colorectal cancer suggested on immunomodulatory function of Gal-1 in the restriction of inflammation. Our results confirmed results of previous studies that systemic levels of proinflammatory cytokines IL-1 and IL-6 are rising during the progression of COVID-19 suggesting on ongoing development of inflammation²⁹. We also found the strong positive correlation between Gal-1 and IL-33 (Table 3). IL-33 is a pleiotropic cytokine that functions as alarmin by stimulating NF- κ B transcriptional factor which further enhances the production of proinflammatory cytokines such as IL-1, IL-6 and promotes inflammation³⁰. Gal-1-IL-33 axis may explain the subsequent correlation between Gal-1 and proinflammatory cytokines IL-1, IL-6 and IL-23 (Table 3). Kazancioglu et al. found that systemic level of Gal-1 is increased in patients with COVID-19 compared to healthy control¹³. In line with this result, we found out that level of Gal-1 increases during the infection and is the highest in patients with stage III (Figure 1). Recent study showed positive association between Gal-1 and disease activity score in patients with Rheumatoid arthritis potentiating Gal-1 as a disease prognostic marker³¹. In accordance with this finding, our results showed for the first time that Gal-1 positively correlated with clinical parameters of COVID-19 such as dry cough and headache, and chest radiographic finding. IL-10 is an immunosuppressive cytokine important for inhibition of functions of T cells, NK cells, macrophages that are important for pathogen elimination but also are the cause of tissue damage³². Van der Leij et al. showed that Gal-1 realizes its immunosuppressive effect by stimulating production of IL-10³³. We believe that in order to prevent and control progression of inflammation and tissue destruction as some kind of compensatory mechanism, immunosuppressive Gal-1 and consequently produced IL-10 increased in parallel with the increment of levels of proinflammatory cytokines and moreover the relation of Gal-1 and proinflammatory cytokines didn't change during COVID-19 progression (Figure 1-2). This assumption is confirmed not only by significant higher serum value of IL-10 in stage III of COVID-19 patients compared to stage I and II, but more importantly, by strong positive correlation that persists between Gal-1 and IL-10.

Our data shows for the first time higher systemic values of galectin 1 in patients with severe COVID-19. The increment of IL-10 and Gal-1 as well as strong positive correlation between them in stage III of COVID-19 implicate on Gal-1 and IL-10 dependent immunomodulation. The

precise mechanism of Gal-1 effect in COVID-19 and its potential as stage marker of disease severity is still to be clarified.

METHODS

Ethical statement

This study was performed in the University Clinical Center of Kragujevac (Covid Center) and Faculty of Medical Sciences (Center for Molecular Medicine and Stem Cell Research), University of Kragujevac, Serbia. All examined subjects gave informed consent. Ethics Committees of the University Clinical Center of Kragujevac (Approval Number 01/20-406) and Faculty of Medical Sciences, University of Kragujevac (Approval Number 01-6776) have given ethical approvals. All research procedures were carried out in accordance with the Declaration of Helsinki and the Principle of Good Clinical Practice.

Patients

This observational and cross-sectional study, from May 2020 to December 2020 included 210 confirmed cases of COVID-19. Real-time reverse transcription–PCR analysis were used for confirmation of COVID-19. 210 hospitalized COVID-19 patients were classified according to disease severity into the three groups: I- Mild group, consisting of 70 patients, with fever (37 - 38°C), fatigue, pharyngalgia, anosmia, nausea, vomiting, headache, dry irritating cough, dyspnea, oxygen saturation, SaO₂ 91%-100%, arterial blood oxygen partial pressure, pO₂ 8. 5- 13. 3 kPa, with normal or weakened / sharpened respiratory noise; normal, interstitial thickening or focal consolidation in CXR lung findings (CXR I, II, III); II- Severe group, consisting of 70 patients with fever of 38-39°C, fatigue, frequent dry irritating cough, dyspnea, myalgia, nausea, vomiting, headache, chest pain, anosmia, SaO₂ 81- 90%, pO₂ 7. 1- 8. 4 kPa, with auscultatory attenuated-inaudible respiratory noise, audible whistling / crackles in the lower segments of the lungs, with focal, multifocal consolidation in CXR lung findings (CRX II, III, IV); III- Critical group, consisting of 70 patients with fever of 39-40°C, frequent dry irritating cough, dyspnea, fatigue, myalgia, nausea, vomiting, headache, chest pain, SaO₂ ≤ 75- 80%, pO₂ ≤ 5- 7 kPa which require high frequency ventilation (HFV), non-invasive mechanical ventilation (Non Invasive Ventilation, NIV) or invasive mechanical ventilation, with auscultatory attenuated-

inaudible respiratory noise, audible whistling / crackles diffusely, with multifocal consolidation, diffuse alveolar changes / ARDS in CXR lung findings (CRX IV, V). Patients included in this study had not been previously treated with statins, corticosteroids, antibiotics, aminosaliclates, immunosuppressants, or any type of biologic therapy for at least two months before enrolling in the study.

Data collection

Suspected COVID-19 patients had their nasopharyngeal swab samples taken and sent to designated authoritative laboratories to detect the SARS-CoV-2. Blood samples were drawn by venous puncture for blood cell counting, D-dimer, analyzes of biochemistry in plasma [urea, glycemia, creatinine, CRP, PCT, CK, AST, ALT, LDH, ALB, BILD, BILT, Fe, Ferritin, K⁺, Na⁺], and for immunoassay. Arterial blood gases (SaO₂, pO₂, partial pressure of carbon dioxide-pCO₂) were drawn and measured several times during the day by ion selective electrode on the automaton. For assessing lung damage, we used CXR digital portable anteroposterior (AP) technique. Radiographic features were described according to Yoon et al.³⁴ following 5-point scoring scale: 1- normal; 2- patchy atelectasis and/or hyperinflation and/or bronchial wall thickening; 3- focal consolidation; 4- multifocal consolidation; and 5- diffuse alveolar changes.

Measurement of cytokines levels in sera

As described in previous study, the blood was collected from patients at 8:00 am³⁵. Sera was separated and stored at -80°C before use. For measurement the concentrations of IL-1 β , IL-6, IL-10, IL-23, IL-33 and Gal-1 in serum samples, we used the commercially available ELISA tests following the instructions of the manufacturer (R&D Systems, Minneapolis, Minn, USA).

Statistical analysis

Statistical Analysis Software IBM SPSS (version 23. 0) was used for performing all data analyses. The significance tests used for suitable purposes were Chi-square test, Student's t-test or Mann–Whitney U test. Data were shown as mean $\pm$ standard error of mean. Pearson's or Spearman's correlation assessed the possible relationship between variables. Strength of correlation was defined as negative or positive weak (-0.3 to -0.1 or 0.1 to 0.3), moderate

(−0.5 to −0.3 or 0.3 to 0.5), or strong (−1.0 to −0.5 or 1.0 to 0.5). Also, basic linear regression model was used in order to identify possible predictors for disease severity. Statistical significance was set at $p < 0.05$.

References:

1. Dhar Chowdhury, S. & Oommen, A. M. Epidemiology of COVID-19. *Journal of Digestive Endoscopy*. **11**, 3-7 (2020).
2. Chen, N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. **395**, 507–13 (2020).
3. Zeng, H. et al. Spectrum and Clinical Characteristics of Symptomatic and Asymptomatic Coronavirus Disease 2019 (COVID-19) With and Without Pneumonia. *Front Med (Lausanne)*. **8**:645651(2021)
4. Chen, L.D. et al. Association between cytokine profiles and lung injury in COVID-19 pneumonia. *Respir Res*. **21**, 201 (2020).
5. Ghazavi, A., Ganji, A., Keshavarzian, N., Rabiemajd, S. & Mosayebi, G. Cytokine profile and disease severity in patients with COVID-19. *Cytokine*. **137**, 155323 (2021).
6. Jacques, F.H. & Apedaile, E. Immunopathogenesis of COVID-19: Summary and Possible Interventions. *Front Immunol*. **11**, 564925 (2020).
7. Cao, X. COVID-19: immunopathology and its implications for therapy. *Nat Rev Immunol* **20**, 269-70 (2020).
8. Caniglia, J.L., Asuthkar, S., Tsung, A.J., Guda, M.R. & Velpula, K.K. Immunopathology of galectin-3: an increasingly promising target in COVID-19. *Fl000Res*. **9**, 1078 (2020).
9. Han, H. et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. *Emerg Microbes Infect*. **9**, 1123-30 (2020).
10. Po-Ku, C. et al. Interleukin-18 Is a Potential Biomarker to Discriminate Active Adult-Onset Still's Disease From COVID-19. *Frontiers in Immunology*. **12**, 2997(2021).
11. Dhirapong, A., Lleo, A., Leung, P., Gershwin, M.E. & Liu, F.T. The Immunological Potential of Galectin-1 and -3. *Autoimmun Rev* **8**, 360–3 (2009).

12. Arciniegas, E., Carrillo, L.M. & Salgado A. Potential Role of Galectin-glycan Lattices in SARS-CoV-2 Infection and Pathogenesis: A Hypothesis. *Explor Res Hypothesis Med.* doi: 10.14218/ERHM.2020.00079 (2021)
13. Kazancioglu, S. et al. Assessment of Galectin-1, Galectin-3, and PGE2 Levels in Patients with COVID-19. *Jpn J Infect Dis.* doi:10.7883/yoken.JJID.2021.020 (2021)
14. World Health Organization. Clinical Management of COVID-19: Interim Guidance. World Health Organization. <https://apps.who.int/iris/handle/10665/332196> (2020)
15. Hu, D. et al. Influence of age and gender on the epidemic of COVID-19 : Evidence from 177 countries and territories-an exploratory, ecological study. *Wiener Klinische Wochenschrift.* **133**, 321-30 (2021).
16. Liu, J. et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. *EBioMedicine.* **55**, 102763 (2020).
17. Wang, D. et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. *JAMA.* **323**, 1061–9 (2020).
18. Rubio-Sánchez, R., Lepe-Balsalobre, E. & Vilorio-Peñas, M. Prognostic factors for the severity of SARS-CoV-2 infection. *Advances in Laboratory Medicine / Avances en Medicina de Laboratorio.* **2**, 253-8 (2021).
19. Albrich, W.C. & Harbarth, S. Pros and cons of using biomarkers versus clinical decisions in start and stop decisions for antibiotics in the critical care setting. *Intensive Care Med.* **41**, 1739–51 (2015).
20. Hu, R., Han, C., Pei, S., Yin, M. & Chen, X.. Procalcitonin levels in COVID-19 patients. *Int J Antimicrob Agents.* **56**, 106051 (2020).
21. Wang, D. et al. Correlation analysis between disease severity and clinical and biochemical characteristics of 143 cases of COVID-19 in Wuhan, China: a descriptive study. *BMC Infect Dis.* **20**, 519 (2020).
22. Cedeno-Laurent, F. & Dimitroff, C.J. Galectin-1 research in T cell immunity: past, present and future. *Clin Immunol.* **142**, 107-16 (2012).
23. Bao, J. et al. Galectin-1 Ameliorates Influenza A H1N1pdm09 Virus-Induced Acute Lung Injury. *Front Microbiol.* **11**, 1293 (2020).

24. Yang, M.L. et al. Galectin-1 binds to influenza virus and ameliorates influenza virus pathogenesis. *J Virol.* **85**, 10010-20 (2011).
25. Ouellet, M. et al. Galectin-1 acts as a soluble host factor that promotes HIV-1 infectivity through stabilization of virus attachment to host cells. *J Immunol.* **174**, 4120-6 (2005).
26. Lei, T. et al. Galectin-1 enhances TNF α -induced inflammatory responses in Sertoli cells through activation of MAPK signalling. *Sci Rep.* **8**, 3741 (2018).
27. Motran, C.C., Molinder, K.M., Liu, S.D., Poirier, F. & Miceli, M.C. Galectin-1 functions as a Th2 cytokine that selectively induces Th1 apoptosis and promotes Th2 function. *Eur J Immunol.* **38**, 3015-27 (2008).
28. Yaseen, H. et al. Galectin-1 Facilitates Macrophage Reprogramming and Resolution of Inflammation Through IFN- β . *Front Pharmacol.* **11**, 901 (2020).
29. Costela-Ruiz, V.J., Illescas-Montes, R., Puerta-Puerta, J.M., Ruiz, C. & Melguizo-Rodríguez, L. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. *Cytokine Growth Factor Rev.* **54**, 62-75 (2020).
30. Choi, Y.S. et al. Nuclear IL-33 is a transcriptional regulator of NF- κ B p65 and induces endothelial cell activation. *Biochem Biophys Res Commun.* **421**, 305-11 (2012).
31. Mendez-Huergo, S.P. et al. Clinical Relevance of Galectin-1 and Galectin-3 in Rheumatoid Arthritis Patients: Differential Regulation and Correlation With Disease Activity. *Front Immunol.* **9**, 3057 (2019).
32. Couper, K.N., Blount, D.G. & Riley, E.M. IL-10: the master regulator of immunity to infection. *J Immunol.* **180**, 5771-7 (2008).
33. van der Leij, J. et al. Strongly enhanced IL-10 production using stable galectin-1 homodimers. *Mol Immunol.* **44**, 506-13 (2007).
34. Yoon, .S.H. et al. Chest Radiographic and CT Findings of the 2019 Novel Coronavirus Disease (COVID-19): Analysis of Nine Patients Treated in Korea. *Korean J Radiol.* **21**, 494-500 (2020).
35. Jovanovic, M. et al. Metabolic syndrome attenuates ulcerative colitis: Correlation with interleukin-10 and galectin-3 expression. *World J Gastroenterol.* **25**, 6465-82 (2019).

Acknowledgments

The authors thank Dusan Tomasevic and Aleksandar Ilic for excellent technical assistance. This work was supported by grant from the Science Fund of the Republic of Serbia (CIBIRDS), Serbian Ministry of Education, Science and Technological Development (175069), project with PR China (06/2018).

Author Contributions statement

Conceptualization, S.S. and I.J.; methodology, S.S., N.G., M.J. (Milena Jurisevic); software, M.J. (Milena Jurisevic); validation, I.J. and Z.D.; formal analysis, M.J. (Milena Jurisevic) ; investigation, S.S., M.J. (Marina Jovanovic), N.G. and M.J. (Milena Jurisevic); resources, N.A.; data curation, B.P.J., Z.M.; writing—original draft preparation, S.S.; writing—review and editing, I.J. and M.J. (Marina Jovanovic*); visualization, N.G., Z.D.; supervision, B.P.J., N.A.; project administration, I.J., N.A.; funding acquisition, N.A., Z.M. All authors have read and agreed to the published version of the manuscript.

Additional information

Competing interests

The authors declare no competing interests.

Figure legends

Figure 1. Serum values of pro-inflammatory and anti-inflammatory cytokines. Based on the disease severity, all COVID-19 patients were divided into three groups: I, II and III. Systemic levels of IL-1 β , IL-6, IL-23, IL-33 and Gal-1 was measured by ELISA. Statistical significance was tested by Mann–Whitney Rank Sum test.

Figure 2. Ratio of Gal-1 and IL-10 with proinflammatory cytokines. Based on the disease severity, all COVID-19 patients were divided in three groups: I, II and III. IL-1 β , IL-6, IL-23, IL-33 and Gal-1 was measured by ELISA. Ratios of Gal-1/IL-1 β , Gal-1/IL-6, Gal-1/IL-23, Gal-1/IL-33, Gal-1/IL-10, IL-10/IL-1 β , IL-10/IL-6, IL-10/IL-23 and IL-10/IL-33 were evaluated for each patient, separately. Statistical significance was tested by Mann–Whitney Rank Sum test.

Table 1. Demographics and clinical characteristics of patients with COVID-19

	Total(n=210)	Mild group (n=70)	Severe group (n=70)	Critical group (n= 70)	P value*
Age mean$\pm$SE		54. 9 $\pm$ 1. 7	59. 5 $\pm$ 1. 3	61. 3 $\pm$ 1. 4	0. 032
Sex					
Female	75(42, 6%)	30(32, 9%)	25(28. 6%)	20(28, 6%)	0. 041
Male	135(57, 14%)	40(64, 2%)	45(71, 4%)	50(71, 4%)	0. 041
Clinical manifestations					
Fever	182(86, 6%)	57(81. 4%)	60 (85, 7%)	65 (92, 8%)	>0. 05
Dry cough	153(72, 8%)	42(60. 0%)	51(72. 8%)	60 (85, 7%)	>0. 05
Fatigue	130(61, 9%)	36(51, 4%)	45(64, 2%)	49(70, 0%)	0. 016
Dyspnea	121(57, 6%)	16(22. 8%)	35(50. 0%)	70(100%)	0. 043
Nausea and vomitung	67(31. 9%)	19(27. 1%)	21(30%)	27(38. 5%)	>0. 05
Myalgia	47(22. 3%)	11(15. 7%)	13(18. 5%)	23(32. 8%)	>0. 05
Anosmia	24(11. 4%)	6(8. 5%)	9(12. 8%)	9(12. 8%)	>0. 05
Headache	79(37, 6%)	24(34, 2%)	26(37%)	29(41. 4%)	>0. 05
Chest pain	15(7. 1%)	3(4. 2%)	6(8. 5%)	6(8. 5%)	>0. 05
Pharyngalgia	7(3. 3%)	4(5. 7%)	2(0. 9%)	1(0. 4%)	>0. 05
Auscultatory findings					
Normal	28(13/3%)	22(31. 4%)	6(8. 5%)	0	0. 000
Attenuated breathing	111(52. 8%)	31(44. 3%)	41(58. 5%)	39(55. 7%)	>0. 05

sound					
Sharpened respiratory sound	30(14. 2%)	5(7. 1%)	10(14. 2%)	15(21. 4%)	>0. 05
Audible cracks diffusly	124(59. 0%)	27(38. 5%)	34(48. 57)	63(90%)	0. 012
Audible whistling	43(20. 4%)	2(2. 8%)	15(21. 4%)	26(37. 1%)	>0. 05
CXR findings					
Normal finding	14(6. 6%)	14(20%)	0(0%)	0(0%)	0. 000
Interstitial thickening	54(25. 7%)	36(51. 4%)	18(25. 7)	0(0%)	0. 000
Focal consolidation	41(19. 5)	20(28. 5%)	21(30. 0%.)	0(0%)	0. 000
Multifocal consolidation	41(19. 5)	0(0%)	31(44. 2%)	10(14. 2%)	0. 000
Diffuse alveolar changes - ARDS	60(28. 5%)	0(0%)	0(0%)	60(85. 7%)	0. 000

Data expressed as mean, standard error (SR), frequency (percentage)

* P values indicate differences between mild, moderate and severe group P < 0. 05 was considered statistically significant

Table 2. Laboratory findings of patients with COVID-19

Measured parametaras	Normal range	Mild	Moderate	Severe	P value*
White blood cell count, $\times 10^9/L$	3. 7-10. 0	6. 6	8. 1	8. 9	>0. 05
Neutrophil count %	44. 0-72. 0	67. 8%	77. 3%	78. 3%	0. 001
Lymphocyte count %	20. 0-46. 0	21. 0%	14. 0%	12. 9%	0. 001
Monocyte count %	2. 0-12. 0	9. 9%	8. 3%	6. 2%	0. 001
Eritrocite count $10^{12}/l$	4. 34-5. 72	4. 5	4. 5	4. 5	>0. 05
Trombocitecount $10^9/l$	135-450	223	237	248	>0. 05
Hemoglobin g/L	138-175	133	132	130	>0. 05
Glucose mmol/L	3. 8-6. 1	6. 9	7. 4	8. 2	>0. 05
Urea mmol/L	3. 0-8. 0	6. 5	6. 7	8. 2	0. 018
Creatinin umol/L	49-106	95. 5	90. 6	93. 2	>0. 05
BILTumol/L	0. 0-21. 0	10	10. 9	11. 7	>0. 05

BIL μ mol/L	0. 0-6. 6	2. 6	3	3. 6	0. 018
AST U/L	0-40	38. 1	52. 8	59. 7	0. 001
ALT U/L	0-40	42	57	64	0. 001
Albumin g/L	35-52	37. 6	34. 6	33. 3	0. 001
LDH U/L	220-450	510. 0	618. 3	830. 5	0. 001
CK U/L	0-171	167. 4	215. 0	247. 0	0. 012
D dimer ug/ml	<0. 50	1. 3	2. 2	3. 2	0. 001
CRP mg/L	0. 0-5. 0	87. 6	92. 4	134. 7	0. 001
PCT ng/mL	0. 5-2. 0	0. 2	0. 6	1. 1	0. 001
pO ₂ kPa	10. 7-13. 3	10. 4	7. 8	6. 6	0. 001
pCO ₂ kPa	4. 7-6. 0	4. 6	4. 7	4. 6	>0. 05
SaO ₂ %	95-98	93. 7	86. 9	73. 3	0. 001
ph	7. 35-7. 45	7. 47	7. 45	7. 45	>0. 05
K ⁺ mmol/L	3. 5-4. 5	3. 9	3. 8	3. 7	>0. 05
Na ⁺ mmol/L	136-145	136. 6	136. 9	134. 5	>0. 05
Fe μ mol/L	6. 6-26	6. 7	6. 3	9. 6	>0. 05
Feritin ug/L	20-300	510. 9	894. 3	1210. 6	0. 001

Table 3. Correlation between Gal-1 and pro- and anti-inflammatory cytokines

	Gal-1					
Clin. stage	I		II		III	
	Pearson`s rho	p value	Pearson`s rho	p value	Pearson`s rho	p value
IL-1 β	0. 089	0. 511	0. 345	0. 004	0. 429	0. 001
IL-6	-0. 150	0. 267	0. 007	0. 955	0. 374	0. 005
IL-10	-0. 121	0. 369	0. 082	0. 509	0. 574	0. 001
IL-23	0. 206	0. 124	0. 603	0. 001	0. 656	0. 001

IL-33	0. 723	0. 001	0. 886	0. 001	0. 869	0. 001
-------	---------------	---------------	---------------	---------------	---------------	---------------

Table 4. Linear regression analysis for dependent variable (COVID-19 severity)

	Unstandardized coefficients (<i>B</i>)	Std. error	Standardized coefficients (beta)	<i>t</i>	<i>p</i>
Age	0. 009	0. 004	0. 172	2. 531	0. 012
Sex (Male)	0. 302	0. 124	0. 166	2. 433	0. 016
Dyspnea	0. 261	0. 115	0. 155	2. 264	0. 025
Fatigue	0. 328	0. 113	0. 198	2. 904	0. 004
Crackles	0. 322	0. 109	0. 200	2. 950	0. 004
Le	0. 042	0. 013	0. 221	3. 265	0. 001
Neutrophil	0. 015	0. 004	0. 284	4. 231	0. 001
Lymphocyte	-0. 020	0. 005	-0. 284	-4. 214	0. 001
Monocyte	-0. 042	0. 010	-0. 278	-4. 129	0. 001
Glucose	0. 038	0. 017	0. 155	2. 266	0. 024
Urea	0. 030	0. 013	0. 159	2. 324	0. 021
BILT	0. 026	0. 013	0. 145	2. 020	0. 045
BILD	0. 104	0. 033	0. 226	3. 197	0. 002
AST	0. 005	0. 001	0. 226	3. 324	0. 001
ALT	0. 003	0. 001	0. 177	2. 604	0. 010
Albumin	-0. 039	0. 009	-0. 287	-4. 283	0. 001
LDH	0. 001	0. 001	0. 414	6. 208	0. 001
CRP	0. 003	0. 001	0. 342	5. 254	0. 001
D dimer	0. 049	0. 019	0. 180	2. 648	0. 009
PCT	0. 276	0. 093	0. 200	2. 958	0. 003

p02	-0. 247	0. 021	-0. 634	-11. 848	0. 001
Sa02	-0. 103	0. 011	-0. 552	-9. 547	0. 001
Feritin	0. 000330	0. 000067	0. 340	4. 938	0. 001
IL-1 β	0. 001	0. 000462	0. 199	2. 739	0. 007
Gal-1	0. 00000709	0. 0000025	0. 207	2. 828	0. 005
IL-6	0. 000446215	0. 0001484	0. 218	3. 007	0. 003
IL-10	0. 00017607	0. 00007588	0. 169	2. 320	0. 021
IL-23	0. 000158	0. 0000524	0. 218	3. 015	0. 003
IL-33	0. 0001782	0. 0000540	0. 240	3. 298	0. 001